CROI 2008: Boston, Massachussetts; February 3-6, 2008

Key Links:

By Topic:



The 15th Conference on Retroviruses and Opportunistic Infections

FEBRUARY 3-6, 2008

Featured Coverage

Management of Treatment-Experienced Patients: CROI 2008 Highlights
In this summary and accompanying slide set, Cal Cohen, M.D., M.S., reviews the latest data on new and developing antiretrovirals for HIV drug-resistant patients, including the CCR5 antagonists vicriviroc and maraviroc (Selzentry, Celsentri); the integrase inhibitor raltegravir (MK-0518, Isentress); the NNRTI etravirine (TMC125, Intelence); and the protease inhibitor darunavir (TMC114, Prezista).

Read Transcript   Listen (19 min.)
Cal Cohen, M.D.

HIV Treatment
Complications of HIV/HAART

David Wohl, M.D.First-Line HIV Therapy and Treatment Strategies: Summary of Research Highlights
In this summary and accompanying slide set, David Wohl, M.D., examines studies investigating the efficacy of atazanavir (Reyataz) and maraviroc (Selzentry, Celsentri) in first-line use; a comparison between abacavir/lamivudine (Epzicom, Kivexa) and tenofovir/emtricitabine (Truvada); data from ACTG 5142 indicating that race and gender can impact treatment success; and sobering new lessons learned from the pivotal SMART study on CD4-guided HIV treatment interruptions.

More Highlights:

David Wohl, M.D.Complications of HIV/HAART: Summary of Research Highlights
In this summary and accompanying slide set, David Wohl, M.D., delves into new research on the use of low-dose growth hormone to treat lipohypertrophy; the point at which fat loss becomes clinically evident; a potential role for chromium supplementation in lipoatrophy treatment; the association between abacavir (Ziagen) -- and, to a lesser extent, didanosine (ddI, Videx) -- and myocardial infarction risk; the impact of HIV, and HIV therapy, on inflammatory markers; and our evolving understanding of the interplay between aging and HIV.

More Highlights:

HIV/Hepatitis Coinfection
HIV Prevention

Megan CraneImmune Reconstitution May Trigger Hepatic Flares in HIV/Hepatitis B Coinfected Patients Starting HAART
Megan Crane, of Monash University in Melbourne, Australia, explores the immunopathogenesis of hepatic flares following the initiation of HAART with anti-hepatitis B activity in patients who are coinfected with HIV and hepatitis B.

More Highlights:

Connie Celum, M.D.Surprisingly, Acyclovir for HSV-2 Treatment Fails to Curtail HIV Acquisition
Connie Celum, M.D., discusses unexpectedly disappointing results from a study examining whether the use of acyclovir to treat herpes simplex virus type-2 infection can, in turn, help reduce a person's risk of HIV acquisition.

More Highlights:

About This Conference

The Body's coverage of the 15th Conference on Retroviruses and Opportunistic Infections (CROI 2008) will include a wide array of individual presentations and symposia, as well as summaries of some of the hottest topics in HIV research.

For more information on CROI 2008, please visit the conference's Web site. You may also view the conference program online.

Funding for coverage of this conference is provided, in part, by Abbott Laboratories.

This coverage was provided by The Body PRO. Copyright © 2008 Body Health Resources Corporation. All rights reserved.

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.